Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fostamatinib- 1 x mannitol-based 38% drug-loaded · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A1 | ACTIVE_COMPARATOR | 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed |
| Part A2 | ACTIVE_COMPARATOR | 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine |
| Part B1 | ACTIVE_COMPARATOR | 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A) |
| Part B2 | ACTIVE_COMPARATOR | 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B) |
| Part B3 | ACTIVE_COMPARATOR | 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) |
| Name | Type | Description |
|---|---|---|
| Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) | DRUG | 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) |
| Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed | DRUG | 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed |
| Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A) | DRUG | 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A) |
| Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B) | DRUG | 1 x 150mg mannitol based 38% drug loaded tablet(batch variant B) |
| Ranitidine | DRUG | 150 mg ranitidine |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study-specific procedures including the genetic sampling and analyses * Volunteers will be males or females aged 18 to 55 years (inclusive) and with a weight of at least 50 kg and body mass index (BMI) betwee...
Fostamatinib- 1 x mannitol-based 38% drug-loaded is a specific oral tablet formulation of fostamatinib developed by AstraZeneca PLC. It is a small molecule drug candidate that has been studied in a Phase 1 clinical trial. The formulation contains 150 mg of fostamatinib with a mannitol-based excipient system at 38% drug loading.
Fostamatinib- 1 x mannitol-based 38% drug-loaded is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical trial evaluating this formulation.
Fostamatinib- 1 x mannitol-based 38% drug-loaded is in Phase 1 clinical development. The single trial for this formulation has been completed. It is an investigational product and has not been approved by the FDA.
Fostamatinib- 1 x mannitol-based 38% drug-loaded has been evaluated in one clinical trial: NCT01682408, titled 'Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability.' This Phase 1 trial was completed and enrolled 28 healthy volunteers in the United States.